Thiazide-induced hyponatraemia: Epidemiology and clues to pathogenesis

Cardiovascular Therapeutics

Volumn 30, Issue 5, 2012, Pages

  Glover, Mark ^a   Clayton, Jenny ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Hypertension; Molecular cardio biology; Renal dysfunction; Vascular biology

Indexed keywords

AQUAPORIN; SODIUM CHLORIDE COTRANSPORTER; THIAZIDE DIURETIC AGENT;

CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GITELMAN SYNDROME; HUMAN; HYPONATREMIA; NEPHRON; PRIORITY JOURNAL; REVIEW; SODIUM ABSORPTION; WATER ABSORPTION;

ANTIHYPERTENSIVE AGENTS; AQUAPORINS; DIURETICS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPONATREMIA; SODIUM; SODIUM CHLORIDE SYMPORTERS; THIAZIDES; WATER;

EID: 84866026111     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2011.00286.x     Document Type: Review

References (87)

1. Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: Report of the fourth working party of the British Hypertension Society, 2004 - BHS IV. J Hum Hypertens 2004;18:139-185.
2. National Institute of Clinical Excellence (NICE). CG34 Hypertension: Full guideline (new recommendations and the evidence they are based on). Available at: http://guidance.nice.org.uk/CG34/Guidance/pdf/English. 2006 [Accessed 5 May 2011].
3. The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002;288:2981-2997.
4. Glover M, Zuber Am, O'Shaughnessy KM. Hypertension, dietary salt intake, and the role of the thiazide-sensitive sodium chloride transporter NCCT. Cardiovasc Ther 2010;1:68-76.
5. Clayton JA, Rodgers S, Blackey J, Avery A, Hall IP. Thiazide diuretic prescription and electrolyte abnormalities in primary care. Br J Clin Pharmacol 2005;61:87-95.
6. Roe PF. Hyponatraemia and diuretics. Lancet 1975;1:1146-1147.
7. Byatt CM, Millard PH, Levin GE. Diuretics and electrolyte disturbances in 1000 consecutive geriatric admissions. R J Soc Med 1990;83:704-708.
8. Clayton JA, Le Jeune IR, Hall IP. Severe hyponatraemia in medical in-patients: Aetiology, assessment and outcome. Q J Med 2006;99:505-511.
9. Ashfar N, Locksley R, Arieff AI. Neurological manifestations and morbidity of hyponatraemia: Correlation with brain water and electrolytes. Medicine (Baltimore) 1976;55:121-129.
10. Leonetti G, Rapelli A, Salvetti A, Scapellato L. Long-term effects of indapamide: Final results of a two year Italian multicentre study in systemic hypertension. Am J Cardiol 1990;65:67H-71H.
11. Elliott WJ, Weber RR, Murphy MB. A double-blind, randomized, placebo-controlled comparison of the metabolic effects of hydrochlorothiazide and indapamide. J Clin Pharmacol 1991;31:751-757.
12. Chow KM, Szeto CC, Wong TY, Leung CB, Li PK. Risk factors for thiazide-induced hyponatraemia. Q J Med 2003;96:911-917.
13. Ashraf N, Locksley R, Arieff AI. Thiazide-induced hyponatraemia associated with death or neurologic damage in outpatients. Am J Med 1981;70:1163-1168.
14. Sharabi Y, Illan R, Kamari T, Cohen H, Nadler M, Messerli FH, Grossman E. Diuretic induced hyponatraemia in elderly hypertensive women. J Hum Hypertens 2002;16:631-635.
15. Abramow M, Cogan E. Clinical aspects and pathophysiology of diuretic-induced hyponatraemia. Adv Nephrol Necker Hosp 1984;13:1-28.
16. Fidler HM, Goldman J, Bielawska CA, Rai GS, Hoffrband BI. A study of plasma sodium levels in elderly people taking amiloride or triamterine in combination with hydrochlorothiazide. Postgrad Med J 1993;69:797-799.
17. Clark BA, Shannon RP, Rosa RM, Epstein FH. Increased susceptibility to thiazide induced hyponatraemia in the elderly. J Am Soc Nephrol 1994;5:1106-1111.
18. Ashouri OS. Severe diuretic-induced hyponatraemia in the elderly. Arch Int Med 1986;146:1355-1357.
19. Sonnenblick M, Friedlander Y, Rosin AJ. Diuretic-induced severe hyponatraemia. Review and analysis of 129 reported patients. Chest 1993;103:601-606.
20. Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G. Mild chronic hyponatraemia is associated with falls, unsteadiness and attention deficits. Am J Med 2006;119:71.e1-8.
21. Kengne FG, Andres C, Sattar L, Melot C, Decaux G. Mild hyponatraemia and risk of fracture in the ambulatory elderly. Q J Med 2008;101:583-588.
22. Adrogue HJ, Madias NE. Hyponatraemia. N Eng J Med 2000;342:1581-1589.
23. Kumar S, Berl T. Sodium. Lancet 1998;352:220-228.
24. Spital A. Diuretic-induced hyponatraemia. Am J Neprol 1999;19:447-452.
25. Fuisz RE, Lauler DP, Cohen P. Diuretic-induced hyponatraemia and sustained antidiuresis. Am J Med 1962;33:783-791.
26. Fichman MP, Vorherr H, Kleeman CR, Telfer N. Diuretic-induced hyponatraemia. Ann Int Med 1971;75:853-863.
27. Hamburger S, Koprivica B, Ellerbeck E, Covinsky JO. Thiazide-induced syndrome of inappropriate secretion of antidiuretic hormone. JAMA 1981;246:1235-1236.
28. Mann SJ. The silent epidemic of thiazide-induced hyponatraemia. J Clin Hypertens 2008;10:477-484.
29. Berl T. Treating hyponatraemia. damed if we do and damned if we don't. Kidney Int 1990;37:1006-1018.
30. Adrogue HJ, Madias NE. Aiding fluid prescription for the dysnatremias. Internsive Care Med 1997;23:309-316.
31. Sterns RH. The treatment of hyponatraemia: First, do no harm. Am J Med 1990;88:557-560.
32. Worthley LI, Thomas PD. Treatment of hyponatraemia seizures with intravenous 29.2% saline. BMJ (Clin Res Ed) 1986;292:168-170.
33. Sarnaik AP, Meert K, Hackbarth R, Fleischmann L. Management of hyponatraemia seizures in children with hypertonic saline: A safe and effective strategy. Crit Care Med 1991;19:758-762.
34. Friedman E, Shadel M, Halkin H, and Farfel Z. Thiazide-induced hyponatremia. Reproducibility by single dose rechallenge and an analysis of pathogenesis. Ann Int Med 1989;110:24-30.
35. Bobulescu IA, Moe W. Luminal Na(+)/H(+) exchange in the proximal tubule. Pflugers arch 2009;458:5-21.
36. Bachmann S, Bostanjoglo M, Schmitt R, Ellison DH. Sodium-transport-related proteins in the mamalian distal nephron- Distribution, ontogeny and functional aspects. Anat Embryol (Berl) 1999;200:447-468.
37. + channel, ROMK. Nat Genet 1996;14:152-156.
38. Simon BD, Karet FE, Hamdan JM, DiPietro A, Sanjad SA, Lifton RP. Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-Cl cotransporter NKCC2. Nat Genet 1996;13:183-188.
39. Simon DB, Nelson-Williams C, Bia MJ, et al. Gitelman's varient of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl transporter. Nat Genet 1996;12:24-30.
40. Simon BD, Bindra RS, Mansfield TA, et al. Mutation in the basolateral Chloride channel CLCNKB, cause Bartter syndrome type III. Nat Genet 1997;17:171-178.
41. Estevez R, Boettger T, Stein V, Birkenhäger R, Otto E, Hildebrandt F, and Jentsch TJ. Barttin is a Cl channel beta-subunit crucial for renal Cl reabsorption and inner K secretion. Nature 2001;414:558-561.
42. Vargas-Poussou R, Huang C, Hulin P, et al. Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome. J Am Soc Nephrol 2002;13:2259-2266.
43. Gitelman HJ, Graham JB, Welt LG. A new familial disorder characterised by hypokalaemia and hypomagnesaemia. Trans Assoc Am Physicians 1966;79:221-235.
44. Gordon R, Geddes R, Pawsey C, O'Halloran W. Hypertension and severe hyperkalaemia associated with suppression of renin and aldosterone and completely reversed by dietary sodium restriction. Aust Ann Med 1970;4:287-294.
45. Disse-Nicodeme S, Achard J, Desitter I, Hout A, Fournier A, Corvol P, Jeunemaitre X. A new locus on chromosome 12p 13.3 for Pseudohypoaldosteronism Type II, an autosomal dominant form of hypertension. Am J Hum Genet 2000;67:302-310.
46. Mansfield TA, Simon DB, Farfel Z, et al. Multilocus linkage of famelial hyperkalaemia and hypertension, famelial yperaldosteronism type II to chromosomes 1q31-42 and 17p11-21. Nat Genets 1997;16:202-205.
47. Liddle GW, Bledsoe T, Coppage WS Jr. A familial renal disorder simulating primary aldosteronism but with negligible aldosterone secretion. Trans Assoc Am Physicians 1963;76:199-213.
48. Chang S, Grunder S, Hanukoglu A, et al. Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, Pseudohypoaldosteronism type I. Nat Genet 1996;12:248-253.
49. Geller D, Farahi A, Pinkerton N, et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000;289:119-123.
50. Sartorato P, Lapeyraque A-L, Armanini D, et al. Different inactivating mutations of the minerolocorticoid receptor in fourteen families affected by Type I Pseudohypoaldosteronism. J Clin Endocrinol Metab 2003;88:2508-2517.
51. Preston GM, Carrol TP, Guggino WB, Agre P. Appearance of water channels in Xenopus Oocytes expressing red cell CHIP28 protein. Science 1992;256:385-387.
52. Litman T, Sogaard R, Zeuthen T. Ammonia and urea permeability of mammalian aquaporins. Hanb Exp Pharmacol 2009;190:327-358.
53. Nejsum LN. The renal plumbing system: Aquarorin water channels. Cell Mol Life Sci 2005;62:1692-1706.
54. Nielsen S, Smith BL, Christensen EI, Agre P. Distribution of the aquaporin CHIP in secretory and resorptive epithelia and capiliary endothelia. Proc Natl Acad Sci USA 1993;90:7275-7279.
55. Robben JH, Knoers NV, Deen PM. Cell biological aspects of the vasopressin type-2 receptor and aquaporin 2 water channel in nephrogenic diabetes insipidus. Am J Physiol Renal Physiol 2006;291:F257-F270.
56. Bichet DG. Lithium, cyclic AMP signaling, A-kinase anchoring proteins, and aquaporin 2. J Am Soc Nephrol 2006;17:920-922.
57. Sands JM, Bichet DG. Nephrogenic diabetes incipidus. Ann Int Med 2006;144:186-194.
58. Glover M, O'Shaughnessy KM. STK39 and WNK Kinases-A new target for blood pressure treatment?Curr Opin Nephrol Hypertens 2011;20:16-22.
59. Subramanya AR, Liu J, Ellison DH, Wade JB, Welling PA. WNK4 diverts the thiazide-sensitive NaCl cotransporter to the lysosome and stimulates AP-3 interaction. J Biol Chem 2009;287:18471-18480.
60. Richardson C, Rafiqi FH, Karlsson HKR, et al. Activation of the thaizide-sensitive Na-Cl cotransporter by the WNK-regulated kinases SPAK and OSR1. J Cell Sci 2008;121:675-684.
61. Glover M, Mercier Zuber A, O'Shaughnessy KM. Renal and Brain Isoforms of WNK3 have opposite effects on NCCT. J Am Soc Nephrol 2009;20:1314-1322.
62. Lin S-H, Shiang J-C, Huang C-C, Yang S-S, Hsu Y-J, Cheng C-J. Phenotype and Genotype Analysis in Chinese Patients with Gitelman's Syndrome. J Clin Endocrinol Metab. 2005;90:2500-2507.
63. Wang Y, O'Connell JR, McArdle PF, et al. Whole-genome association study identifies STK39 as a hypertension susceptibility gene. Proc Natl Acad Sci USA 2009;106:226-231.
64. Rafiqi FH, Mercier Zuber A, Glover M, et al. Role of the WNK-activated SPAK kinase in regulating blood pressure. EMBO Mol Med 2010;2:1-13.
65. Clayton JA. The pharmacoepidimiology of hyponatraemia. Thesis/dissertation, University of Nottingham, 2006.
66. Gagnon KBE, England R, Diehl L, Delpire E. Apoptosis-associated tyrosine kinase scaffolding of protein phosphatase 1 and SPAK reveals a novel pathway for Na-K-Cl cotransporter regulation. Am J Physiol Cell Physiol 2007;292:C1809-C1815.
67. Glover M, Zuber AM, Figg N, O'Shaughnessy KM. The activity of the thiazide-sensitive Na+Cl-Cotransporter is regulated by protein phosphatase, PP4. Can J Physiol Pharmacol 2010;88:986-995.
68. Scholl UI, Choi M, Liu T, et al. Seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance (SeSAME syndrome) caused by muttaions in KCNJ10. Proc Natl Acad Sci USA 2009;106:5842-5847.
69. Dimke H, San Cristobal P, de Graaf M, Lenders JW, Deinum J, Hoenderop JG, Bindels R. Gamma adducin stimulates the thiazide-sensitive NaCl cotransporter. J Am Soc Nephrol 2011;22:508-517.
70. San Cristobal P, Pacheco-Alvarez D, Richardson C, et al. Angiotensin II signaling increases activity of the renal NaCl cotransporter through a WNK4-SPAK dependent pathway. Proc Natl Acad Sci USA 2009;106:4384-4389.
71. Magaldi AJ. New insights into the paradoxical effect of thiazides in diabetes insipidus therapy. Nephrol Dial Transplant. 2000;15:1903-1905.
72. Cesar KR, Magaldi AJ. Thiazide induces water absorption in the inner medullary collecting duct of normal and Brattleboro rats. Am J Physiol Renal Physiol 1999;277:756-760.
73. Simon DB, Nelson-Williams C, Bia MJ, et al. Gitelman's varient of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl transporter. Nat Genet. 1996;12:24-30.
74. Schepkens H, Stubbe I, Hoeben H, Vanholder R, Lameire N. Severe hyponatraemia and hypouricaemia in Gitelman's syndrome. Nephrol Dial Transplant. 2001;16:2250-2252.
75. Weizhen J, Foo JN, O'Roak BJ, et al. Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat Genet. 2008;5:592-599.
76. Romeo S, Yin W, Kozlitina J, Pennacchio LA, Boerwinkle E, Hobbs HH, Cohen JC. Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J Clin Invest. 2009;119:70-79.
77. Uwai Y, Saito H, Hashimoto Y, Inui K-I. Interaction and transport of thiazide diuretics, loop diuretics and acetazolamide via rat renal organic anion transporter rOAT1. J Pharmacol Expt Ther 2000;295:1261-265.
78. Beermann B, Groschinsky-Grind M, Lindstrom B. Pharmacokinetics of Bendroflumethiazide. Clin Pharmacol Ther 1977;22:385-388.
79. Delaloy C, Lu J, Hounot AM, Disse-Nicodeme S, Gasc JM, Corvol P, Jeunemaitre X. Multiple promotors in the WNK1 gene: One controls the expression of a kidney-specific kinase-defective isoform. Mol Cell Biol 2003;23:9208-9221.
80. The SEARCH collaborative group. SLCO1B1 varients and statin-induced-myopathy-A genomewide study. N Eng J Med 2008;359:789-799.
81. Singer JB, Lewitzky S, Leroy E, et al. A genome-wide study identifies HLA alleles associated with lumaricoxib-related liver injury. Nat Genet 2010;42:711-716.
82. Hautekeete ML, Horsmans Y, Van Waeyenberge C, et al. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology 1999;117:1181-1186.
83. J O'Donohue, K Oien, P Donaldson, J Underhill, M Clare, R MacSween, P Mills. Co-amoxiclav jaundice: Clinical and histological features and HLA class II association. Gut 2000;47:717-720.
84. Chung WH, Hung SI, Hong HS, et al. A marker for Stevens-Johnson syndrome. Nature 2004;428:486.
85. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002;359:727-732.
86. Kindmark A, Jawaid A, Harbron CG, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 2010;8:186-195.
87. O'Shaughnessy KM. HapMap, pharmacogenomics, and the goal of personalized prescribing. Br J Clin Pharmacol 2006;61:783-786.